Farshid Dayyani

41PUBLICATIONS
130CO-AUTHORS
HaematologyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Life cycle assessment and industrial ecologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (41)

|Oct 24, 2026
Outcomes by Comorbidities with Tremelimumab and Durvalumab in the Randomized, Controlled Phase 3 HIMALAYA Study in Unresectable Hepatocellular Carcinoma.

|Jul 23, 2026
Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial.

|Jun 30, 2026
A Randomized Phase II Study of Combination Atezolizumab and Varlilumab (CDX-1127) with or without Cobimetinib in Previously Treated Unresectable Biliary Tract Cancer.

|May 04, 2026
Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial.

|Mar 14, 2026
Regional Therapies Utilized in Treating Unresectable Colorectal Adenocarcinoma with Peritoneal Metastases.

Shray Malik, Vanessa Le, Farshid Dayyani

|Feb 27, 2026
Utility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant Therapy.

Sakti Chakrabarti, Stacey A Cohen, Antony Tin

Pageof 7

Frequent Collaborators

5 joint publications

Nadine Abi-Jaoudeh

5 joint publications

Aditya Mahadevan

3 joint publications

Dayantha M Fernando

3 joint publications

Gregory P Botta